Tafamidis (INN, or Fx-1006A, trade name Vyndaqel) is a drug for the amelioration of transthyretin-related hereditary amyloidosis (also familial amyloid polyneuropathy, or FAP), a rare but deadly neurodegenerative disease. The drug was approved by the European Medicines Agency in November 2011 and by the Japanese Pharmaceuticals and Medical Devices Agency in September 2013.

CAS：594839-88-0
中文别名：2-(3,5-二氯苯基)-6-苯并噁唑羧酸;
英文别名：TAFAMIDIS;8FG9H9D31J;UNII-8FG9H9D31J;FX-1006;3MI;2-(3,5-Dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid;
分子式：C14H7Cl2NO3
分子量：308.116
精确质量：306.98
Psa：63.33
Logp：4.4998

UNII：8FG9H9D31J

密度：1.53